Abstract
Purpose/objective Prospectively assessing clinical/dosimetry factors affecting the acute worsening of urinary functionality after radiotherapy for prostate cancer. Material/methods DUE01 population was considered, including patients treated with conventional or moderate hypo-fractionation (2.2-2.7 Gy/fr). Relevant clinical factors were collected, urinary symptoms were self-reported through the International Prostate Symptom Score (IPSS) before and at the end of radiotherapy; while absolute weekly dose-surface histograms (DSHw) were chosen as dosimetry descriptors. An IPSS increase of at least 10 and 15 points (ΔIPSS ≥ 10 and ΔIPSS ≥ 15) were chosen as endpoints. Patients with baseline IPSS > 20 were excluded. Relevant factors were chosen through a bootstrap-based in silico methodology. Results Complete information was available for 380 patients: 77/380 (20%) and 28/380 (7%) with ΔIPSS ≥ 10 and ΔIPSS ≥ 15, respectively. Neoadjuvant hormone was protective (OR = 0.49 and 0.69). DSHw at 8.5 Gy/week and 12 Gy/week were risk factors, with additional risk for patients who use cardiovascular drugs and anti-hypercholesterolemia drugs. In the hypo-fractionated subgroup (n = 209) the role of cardiovascular drugs (OR = 2.16) for ΔIPSS ≥ 10 and anti-hypercholesterolemia drugs (OR = 2.80) for ΔIPSS ≥ 15, together with DSHw (10 Gy/week and 12.5 Gy/week, respectively), was confirmed. Conclusion Current study shows a dose-surface/volume effect for acute large worsening of urinary functionality; several clinical variables largely impact the risk and especially all the factors related with vascular diseases.
| Original language | English |
|---|---|
| Pages (from-to) | 92-98 |
| Number of pages | 7 |
| Journal | Radiotherapy and Oncology |
| Volume | 118 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 1 2016 |
Fingerprint
Keywords
- Dose-volume effects
- Prostate cancer
- Radiotherapy
- Urinary toxicity
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging
- Hematology
Cite this
Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy. / Palorini, Federica; Rancati, Tiziana; Cozzarini, Cesare; Improta, Ilaria; Carillo, Viviana; Avuzzi, Barbara; Casanova Borca, Valeria; Botti, Andrea; Degli Esposti, Claudio; Franco, Pierfrancesco; Garibaldi, Elisabetta; Girelli, Giuseppe; Iotti, Cinzia; Maggio, Angelo; Palombarini, Marcella; Pierelli, Alessio; Pignoli, Emanuele; Vavassori, Vittorio; Valdagni, Riccardo; Fiorino, Claudio.
In: Radiotherapy and Oncology, Vol. 118, No. 1, 01.01.2016, p. 92-98.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy
AU - Palorini, Federica
AU - Rancati, Tiziana
AU - Cozzarini, Cesare
AU - Improta, Ilaria
AU - Carillo, Viviana
AU - Avuzzi, Barbara
AU - Casanova Borca, Valeria
AU - Botti, Andrea
AU - Degli Esposti, Claudio
AU - Franco, Pierfrancesco
AU - Garibaldi, Elisabetta
AU - Girelli, Giuseppe
AU - Iotti, Cinzia
AU - Maggio, Angelo
AU - Palombarini, Marcella
AU - Pierelli, Alessio
AU - Pignoli, Emanuele
AU - Vavassori, Vittorio
AU - Valdagni, Riccardo
AU - Fiorino, Claudio
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Purpose/objective Prospectively assessing clinical/dosimetry factors affecting the acute worsening of urinary functionality after radiotherapy for prostate cancer. Material/methods DUE01 population was considered, including patients treated with conventional or moderate hypo-fractionation (2.2-2.7 Gy/fr). Relevant clinical factors were collected, urinary symptoms were self-reported through the International Prostate Symptom Score (IPSS) before and at the end of radiotherapy; while absolute weekly dose-surface histograms (DSHw) were chosen as dosimetry descriptors. An IPSS increase of at least 10 and 15 points (ΔIPSS ≥ 10 and ΔIPSS ≥ 15) were chosen as endpoints. Patients with baseline IPSS > 20 were excluded. Relevant factors were chosen through a bootstrap-based in silico methodology. Results Complete information was available for 380 patients: 77/380 (20%) and 28/380 (7%) with ΔIPSS ≥ 10 and ΔIPSS ≥ 15, respectively. Neoadjuvant hormone was protective (OR = 0.49 and 0.69). DSHw at 8.5 Gy/week and 12 Gy/week were risk factors, with additional risk for patients who use cardiovascular drugs and anti-hypercholesterolemia drugs. In the hypo-fractionated subgroup (n = 209) the role of cardiovascular drugs (OR = 2.16) for ΔIPSS ≥ 10 and anti-hypercholesterolemia drugs (OR = 2.80) for ΔIPSS ≥ 15, together with DSHw (10 Gy/week and 12.5 Gy/week, respectively), was confirmed. Conclusion Current study shows a dose-surface/volume effect for acute large worsening of urinary functionality; several clinical variables largely impact the risk and especially all the factors related with vascular diseases.
AB - Purpose/objective Prospectively assessing clinical/dosimetry factors affecting the acute worsening of urinary functionality after radiotherapy for prostate cancer. Material/methods DUE01 population was considered, including patients treated with conventional or moderate hypo-fractionation (2.2-2.7 Gy/fr). Relevant clinical factors were collected, urinary symptoms were self-reported through the International Prostate Symptom Score (IPSS) before and at the end of radiotherapy; while absolute weekly dose-surface histograms (DSHw) were chosen as dosimetry descriptors. An IPSS increase of at least 10 and 15 points (ΔIPSS ≥ 10 and ΔIPSS ≥ 15) were chosen as endpoints. Patients with baseline IPSS > 20 were excluded. Relevant factors were chosen through a bootstrap-based in silico methodology. Results Complete information was available for 380 patients: 77/380 (20%) and 28/380 (7%) with ΔIPSS ≥ 10 and ΔIPSS ≥ 15, respectively. Neoadjuvant hormone was protective (OR = 0.49 and 0.69). DSHw at 8.5 Gy/week and 12 Gy/week were risk factors, with additional risk for patients who use cardiovascular drugs and anti-hypercholesterolemia drugs. In the hypo-fractionated subgroup (n = 209) the role of cardiovascular drugs (OR = 2.16) for ΔIPSS ≥ 10 and anti-hypercholesterolemia drugs (OR = 2.80) for ΔIPSS ≥ 15, together with DSHw (10 Gy/week and 12.5 Gy/week, respectively), was confirmed. Conclusion Current study shows a dose-surface/volume effect for acute large worsening of urinary functionality; several clinical variables largely impact the risk and especially all the factors related with vascular diseases.
KW - Dose-volume effects
KW - Prostate cancer
KW - Radiotherapy
KW - Urinary toxicity
UR - http://www.scopus.com/inward/record.url?scp=84959533025&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959533025&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2015.11.036
DO - 10.1016/j.radonc.2015.11.036
M3 - Article
AN - SCOPUS:84959533025
VL - 118
SP - 92
EP - 98
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
SN - 0167-8140
IS - 1
ER -